Introduction to Accelerate.EU Project
A new and innovative initiative known as Accelerate.EU aims to create a comprehensive value chain for Astatine-211, a promising isotope in cancer therapy. This ground-breaking project, led by IBA (Ion Beam Applications S.A.) in partnership with the Jules Bordet Institute, is designed to improve patient access to cutting-edge cancer treatments across Europe. By receiving funding from the European Commission, Accelerate.EU is set to make significant strides in the field of alpha therapies.
Strategic Goals and Expected Impact
The Accelerate.EU project, which is valued at EUR 16 million, has ambitious objectives. The main goal is to establish a resilient and strategic system for the production and application of Astatine-211. With a five-year timeline, this initiative endeavors to enhance the availability of advanced cancer treatments, targeting diseases like triple-negative breast cancer, pancreatic cancer, and glioblastoma.
Collaboration and Funding
The European Commission has committed EUR 8 million to fund this transformative project through the Innovative Health Initiative (IHI). This funding is paralleled by significant in-kind contributions from affiliated industry partners. Accelerate.EU unites a coalition of 17 leading institutions and companies from nine different countries, merging academic knowledge with industry expertise to fuel innovation in cancer treatments.
Innovative Therapeutic Approaches
At the core of the Accelerate.EU initiative is Astatine-211, an alpha-emitting radioisotope known for its potential in treating aggressive cancers. The project will develop and validate novel radiotheranostic agents to fulfill urgent clinical needs, enhancing the capabilities for both production and patient treatment.
Streamlined Processes for Patient Access
One of the unique aspects of the Accelerate.EU project is its approach to integrating the entire value chain—from research to clinical application. The initiative focuses on ensuring timely access for patients to Astatine-211 therapies. Moreover, it will incorporate co-clinical strategies, conducting clinical and preclinical studies simultaneously to identify patients who would benefit the most from these innovative treatments.
Expert Insights on the Project
Hugo Levillain, Project Lead Coordinator at the Jules Bordet Institute, highlighted the importance of Accelerate.EU in advancing cancer research. He emphasized the project's potential to streamline Astatine-211 production and distribution throughout Europe, making a significant impact on patient care.
The Role of IBA
Charles Kumps, President at IBA RadioPharma Solutions, expressed pride in IBA's involvement in this transformative project. As the foremost global expert in particle accelerator technology, IBA aims to leverage its advanced solutions to develop Astatine-211 theranostics, thereby accelerating both production and clinical applications for cancer treatment.
Future Developments and Training
The Accelerate.EU project is committed to developing a stable and reliable supply chain for Astatine-211, ensuring this vital treatment reaches more patients across Europe. Additionally, there will be a strong emphasis on creating educational resources to enhance the implementation of these innovative solutions and support long-term knowledge sharing within the region.
About IBA
IBA is recognized as the global leader in particle accelerator technology, primarily focused on proton therapy—the most advanced form of radiation therapy. Headquartered in Louvain-la-Neuve, Belgium, IBA employs around 2,000 individuals and holds a certified B Corporation status, demonstrating its commitment to social and environmental performance. As a prominent player in industrial sterilization, radiopharmaceuticals, and dosimetry, IBA continues to advance healthcare solutions worldwide.
Contact Information
For more information about the Accelerate.EU project or IBA, please contact:
Olivier Lechien
Corporate Communication Director
Phone: +32 10 475 890
Email: communication@iba-group.com
Frequently Asked Questions
What is the main goal of the Accelerate.EU project?
The main goal is to establish a comprehensive production and clinical application chain for Astatine-211, enhancing access to innovative cancer treatments across Europe.
How much funding has the Accelerate.EU project received?
The project has received EUR 8 million in funding from the European Commission, complemented by in-kind contributions from industry partners.
Which cancers are targeted by Astatine-211 therapies?
Astatine-211 therapies are particularly aimed at treating aggressive cancers, including triple-negative breast cancer, pancreatic cancer, and glioblastoma.
Who are the key partners in the Accelerate.EU project?
The project involves collaboration among 17 leading institutions and companies from nine European countries, combining academic and industrial expertise.
What role does IBA play in the project?
IBA plays a pivotal role as the project leader, contributing its expertise in particle accelerator technology to enhance the development and production of Astatine-211 for cancer therapies.
